In 2025, Belarus’ pharmaceutical industry enhanced its standing both within the country and abroad. Belarusian firms continue to offer a wide range of products, with more than 1,600 different medications available across multiple pharmacotherapeutic groups. A large share of these medicines is manufactured by companies under the Belpharmprom Holding, which produces over 700 drugs — as noted by Healthcare Minister Aleksandr Khodzhayev.
“Domestic medicines hold a significant share in the local market. By value, they account for 50.1 percent, which is one of the highest rates among neighbouring countries. In terms of actual consumption, their share is even greater: about 65 percent of pharmacy sales and more than 80 percent in hospitals. This distribution is due to the significant price gap between imported and Belarusian medicines —domestic drugs are typically three times less expensive, making them more affordable for most patients and appealing for government purchases,” Mr. Khodzhayev emphasised.
Export figures also show steady growth. In 2025, medicine exports reached $222.1m, marking an increase of over 7 percent compared to the previous year. About one-third of all medicines produced are delivered abroad, and the range of export destinations has broadened: Belarusian medicines were sent to 30 countries worldwide, up from 26 the year before. The Belpharmprom Holding remains the key exporter, accounting for two-thirds of all foreign shipments.
“The industry continues to update its product range: 55 new domestic medicines were registered over the year, including developments from the holding’s enterprises and the National Academy of Sciences,” the Healthcare Minister pointed out. “At the same time, the pricing policy remains focused on affordability. Most of Belpharmprom’s products are priced at up to $2, with one-third costing less than $1. These prices are significantly lower than those of private manufacturers’ equivalents and imported medicines, helping to maintain socially important accessibility of drugs.”
